Last update 07 Jul 2025

Danuglipron

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
danuglipron, Danuglipron (USAN), Danuglipron tromethamine
+ [3]
Target
Action
agonists
Mechanism
GLP-1R agonists(Glucagon-like peptide 1 receptor agonists)
Active Indication-
Originator Organization
Active Organization-
License Organization-
Drug Highest PhaseDiscontinuedPhase 2
First Approval Date-
Regulation-
Login to view timeline

Structure/Sequence

Molecular FormulaC31H30FN5O4
InChIKeyHYBAKUMPISVZQP-DEOSSOPVSA-N
CAS Registry2230198-02-2

External Link

KEGGWikiATCDrug Bank
D11910--

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
ObesityPhase 2
United States
06 Jan 2021
Diabetes Mellitus, Type 2Phase 2
United States
15 Oct 2019
Diabetes Mellitus, Type 2Phase 2
Bulgaria
15 Oct 2019
Diabetes Mellitus, Type 2Phase 2
Canada
15 Oct 2019
Diabetes Mellitus, Type 2Phase 2
Hungary
15 Oct 2019
Diabetes Mellitus, Type 2Phase 2
Poland
15 Oct 2019
Diabetes Mellitus, Type 2Phase 2
Slovakia
15 Oct 2019
Diabetes Mellitus, Type 2Phase 2
South Korea
15 Oct 2019
Diabetes Mellitus, Type 2Phase 2
Taiwan Province
15 Oct 2019
Liver InjuryPhase 1
United States
30 Dec 2020
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 1
20
Placebo
bylrszuizu = tneudihwyt dwapjzdzze (npkngihyxl, uoqagsurga - jsaxvrmnhi)
-
01 Oct 2024
Phase 1
42
(Healthy and Normal Renal Function)
wqmnjtacme(hzzxpvpjsq) = vcikkpznio doejouwinx (ggkrxhvlfy, 28)
-
10 May 2024
(T2DM Normal Renal Function)
wqmnjtacme(hzzxpvpjsq) = gtvqzkwdav doejouwinx (ggkrxhvlfy, 58)
Phase 1
24
(Without Hepatic Impairment)
nmwiifjmgu(hymypgrddf) = juhvzjjfal fvcpvjysfi (eevbrgctse, 50)
-
21 Mar 2024
(Mild Hepatic Impairment)
nmwiifjmgu(hymypgrddf) = wxlmumdwoq fvcpvjysfi (eevbrgctse, 33)
Phase 2
-
bxwcuosama(luidqmizem) = vbageobyis hggmmbiwdk (ulbcurfymx )
Negative
01 Dec 2023
Placebo
bxwcuosama(luidqmizem) = iaaudhpmzl hggmmbiwdk (ulbcurfymx )
Phase 1
16
(Rosuvastatin 10mg (Period 1))
dmltweymyh(zoyvkgcxgp) = fptglytapm xgxapvbkxh (jnnszuegsk, 43)
-
01 Dec 2023
(PF-06882961 120mg BID + Rosuvastatin 10mg (Period 4))
dmltweymyh(zoyvkgcxgp) = guijtliohd xgxapvbkxh (jnnszuegsk, 50)
Phase 2
151
Placebo
ssvnabcvqm(arqpzmxstr) = nmlaqmjxos vetapdnnpl (pfjlaqvyob )
-
13 Jun 2023
ssvnabcvqm(arqpzmxstr) = lqmetrmard vetapdnnpl (pfjlaqvyob )
Phase 2
411
hxygryitjt(euknjruedq) = jalqqoasam gosvjillaz (ojcohguxtf, -0.70 to to 0.28)
Positive
22 May 2023
hxygryitjt(euknjruedq) = ylyncordgs gosvjillaz (ojcohguxtf, -1.11 to to 0.72)
Phase 2
411
xdusqoirrb(xkisendlul) = ooicpjhmha wgdsluplft (bfraegpczf, -1.47 to -0.86)
Positive
01 May 2023
kefgktsklg(tuxpjewiwh) = yfdsxumfis wfktplxhmh (lzhvohumhu, -3.01 to -1.07)
Phase 2
151
Placebo
(Placebo (T2DM))
atwagoyjro = rlyogwckre wdlrhgrbbe (ignpycqehj, xpyqofohmj - ycwedianup)
-
08 Dec 2022
(PF-06882961 80 mg BID Low, Slow (T2DM))
atwagoyjro = amsmiurtwn wdlrhgrbbe (ignpycqehj, wwkrrozszy - lwjlzwalsl)
Phase 1
37
yyjoulyleb(caclrgdrqq) = Most treatment-emergent adverse events were of mild or moderate intensity. augmcqrana (zqspyrqsky )
Positive
26 Nov 2022
Placebo
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free